Brasão Governo de São Paulo

In compliance with Brazilian electoral legislation, the contents of this website will not be updated until the end of election in October.

The Institute


About us


With 121 years of history, Butantan works to prevent deseases like Covid-19, flu, tetanus, diphtheria, hepatitis A and B, chikungunya, whooping cough, dengue, HPV and rabies. In 2021, Butantan produced:

  • 100 million doses of Covid-19 vaccine
  • 80 million doses of flu vaccine
  • 28 million doses of vaccines Against hepatitis A and B, HPV, DTaP and rabies
  • 560 thousand units of serum against venoms, bacterial toxins and the rabies virus
Download the institutional presentation in PDF of the Instituto Butantan

Instituto Butantan is the main producer of immunobiologicals in Brazil. It is responsible for a considerable percentage of the national production of hyperimmune sera and vaccine antigens, which make up the vaccines used in the National Immunization Program (Programa Nacional de Imunizações, PNI) of the Brazilian Ministry of Health. Our technological development activities in the production of health inputs are associated with the production of vaccines, antitoxins and antivenoms, and biopharmaceuticals for human use.

Our course of action

Official documents

Decree no. 878-A, of February 23, 1901- Law providing for the Instituto Serumtherapico, predecessor of Instituto Butantan.

Decree no. 64,518, of October 10, 2019- Law providing for the reorganization of Instituto Butantan.